CIPLA vs INDOCO: Stock Comparison

Cipla Ltd vs Indoco Remedies Limited

Live data: 22 July 2026, 2:34 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a higher ROE, a higher dividend yield and lower leverage, while Indoco Remedies Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Indoco Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 7 of 13 scored metrics and INDOCO on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹2,183 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 29.83x
P/B Ratio
INDOCO has a lower P/B
2.41x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹-10.71
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0.08%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs -2.1%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -54.6%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAINDOCO
Live Price₹1,410.9₹233.76
Day Change-1.51%-4.91%
Volume12.88 L70,796
52-Week High₹1,673₹336
52-Week Low₹1,165.7₹162.19
Distance from 52W High-15.67%-30.43%

Valuation

MetricCIPLAINDOCO
Market Cap₹1.14 L Cr₹2,183 Cr
P/E Ratio29.83x-23.83x
P/B Ratio3.36x2.41x
EPS₹48.01₹-10.71
Book Value₹426.25₹111.55
Dividend Yield0.9%0.08%

Growth

MetricCIPLAINDOCO
Revenue Growth (TTM YoY)-2.1%21.9%
EPS Growth (TTM YoY)-54.6%0%
Qtr Sales Growth-2.8%21.9%
Qtr Profit Growth-54.6%39%

Profitability & Leverage

MetricCIPLAINDOCO
ROE11.6%-9.42%
ROCE15.5%0.93%
Net Margin13.96%-5.31%
Operating Margin20.9%7.68%
Debt to Equity0.02x1.16x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLAINDOCO
Promoter Holding9.17%58.86%
FII Holding22.56% 1.37 pp1.27% 0.33 pp
DII Holding31.97% 1.25 pp17.68% 0.47 pp
Public Holding16.25% 0.12 pp22.04% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Indoco Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.